|
Price: $2.3900
$-0.11 
-4.400%
|
| Day's High:
| $2.64
| Week Perf:
| -13.09 %
|
| Day's Low: |
$ 2.32 |
30 Day Perf: |
-20.6 % |
| Volume (M): |
82 |
52 Wk High: |
$ 17.49 |
| Volume (M$): |
$ 196 |
52 Wk Avg: |
$6.45 |
| Open: |
$2.49 |
52 Wk Low: |
$2.32 |
|
|
| Market Capitalization (Millions $) |
14 |
| Shares
Outstanding (Millions) |
6 |
| Employees |
45 |
| Revenues (TTM) (Millions $) |
10 |
| Net Income (TTM) (Millions $) |
-45 |
| Cash Flow (TTM) (Millions $) |
-4 |
| Capital Exp. (TTM) (Millions $) |
0 |
Curis Inc
Curis Inc is a biotechnology company that focusses on developing innovative cancer therapies. Founded in 2000, the company is headquartered in Lexington, Massachusetts. Curis has a strategic collaboration with Aurigene and is known for its expertise in precision medicine and small molecule drug development.
The company's primary goal is to discover and develop novel targeted therapies for the treatment of various cancers. They utilize a proprietary drug discovery platform to identify potential drug candidates, focusing on signaling pathways and targeted proteins that play crucial roles in tumor growth and survival.
Curis has several drug candidates in its pipeline, with some in various stages of clinical development. Their lead candidate, CUDC-907, is being evaluated for the treatment of hematological cancers such as lymphoma. The company also has collaborations with other pharmaceutical companies to advance the development of their drug candidates.
Curis has a dedicated team of scientists and researchers who work towards translating scientific discoveries into potential cancer treatments. The company aims to bring innovative therapies to patients and improve outcomes in oncology.
In summary, Curis Inc is a biotechnology company that specializes in the development of targeted cancer therapies. With a focus on precision medicine and small molecule drug development, the company aims to make a significant impact in the field of oncology.
Company Address: 128 Spring Street Lexington 2421 MA
Company Phone Number: 503-6500 Stock Exchange / Ticker: NASDAQ CRIS
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Curis Inc
Curis Inc, a biotechnology and pharmaceutical company, has experienced a significant surge in its stock price in recent trading days. Despite reporting lower revenue and a larger shortfall during the Q1 2024 earnings season, the company's stock continues to trend higher. This article will explore the impact of these financial results on Curis Inc's future prospects.
1. Stock Gains and Positive Year-to-Date Performance:
Curis Inc's stock has witnessed a remarkable 14.1% increase over the last five trading days. Furthermore, the company has extended its year-to-date gains to an impressive 32.61%. This performance highlights the market's confidence in Curis Inc's ability to weather challenges and generate long-term value.
|
| Curis Inc
Financial results for Curis Inc for the fiscal time-frame ending December 31, 2023, reveal mixed performance with some concerning trends. The company saw a widening of diminishing returns, with a loss per share of $-0.12 compared to $-0.11 in the previous year. However, earnings per share improved from $-2.13 to $-8.96 per share.
Revenue also took a hit, depreciating by -6.616% to $2.70 million, down from $2.89 million in the same period a year prior. Sequentially, revenue decreased by -4.836% from $2.83 million. This contrasts with the performance of the Biotechnology & Pharmaceuticals industry as a whole, which saw a revenue growth of 9.84% in the fourth quarter of 2023 compared to the previous year.
|
| Curis Inc
Curis Inc, a biotechnology and pharmaceutical company, recently released its latest fiscal report, revealing mixed results for the most recent period. The company reported a significant increase in its deficit per share, reaching $-2.13 per share compared to $-0.14 in the previous year's fiscal period. Additionally, the deficit advanced from $-0.12 per share from the preceding financial reporting period.
Despite the negative news about the deficit, Curis Inc did experience some positive growth in its revenue. The company saw a slight increase of 0.283% in revenue, reaching $2.83 million from $2.83 million in the corresponding financial reporting period a year prior. Moreover, the revenue improved sequentially by 28.949% from $2.20 million.
|
| Curis Inc
Curis Inc, a prominent player in the Biotechnology & Pharmaceuticals sector, recently released its financial results for the April to June 30, 2023 period. The report highlights a decline in revenue, lower orders, and increased shortfall compared to the previous year. This article will analyze these outcomes and explore the potential impacts they might have on the company's future prospects.
Revenue Decline and Lower Orders:
During the reported period, Curis Inc witnessed a significant decline in revenue. The figures dropped by 8.191% to $2.20 million, compared to the previous year's revenue of $2.30 million. This decline can be attributed to lower orders, which resulted in diminishing revenue streams. The main concern for the company is the inability to maintain stable revenue growth, especially when compared to the overall improvement seen in the Biotechnology & Pharmaceuticals sector.
|
| Curis Inc
Curis Inc, a clinical-stage biotechnology company, recently reported its financial performance for the first quarter of the fiscal year 2023, ending on March 31st. According to the company's financial report, Curis recorded revenue of $2.30 million, which represented an 11.667% increase from the same period of the previous year. Despite the positive revenue growth, the company's net deficit per share stood at $-0.12, indicating that Curis ended the quarter in the red.
Comparing the latest revenue and deficit figures to the previous quarter, Curis recorded a decline of -20.436% from revenue of $2.89 million. Moreover, the advanced deficit increased from $-0.11 per share. These numbers suggest that while the company's revenue growth may have been positive compared to previous years, it was not consistent over the last few quarters.
|
| Per Share |
Current |
| Earnings (TTM) |
-5.9 $ |
| Revenues (TTM) |
1.73 $
|
| Cash Flow (TTM) |
- |
| Cash |
3.51 $
|
| Book Value |
-
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-5.9 $
|
| Revenues (TTM) |
1.73 $ |
| Cash Flow (TTM) |
- |
| Cash |
3.51 $
|
| Book Value |
- |
| Dividend (TTM) |
0 $ |
|
|
|
|
